Abstract:Background Expression of the long non-coding RNA (lncRNA) LOC285194 was previously shown to be correlated with aggressive clinicopathological features and poor prognosis in several cancers. The aim of the present study was to explore the relationship between LOC285194 expression and clinical outcomes in esophageal squamous cell carcinoma (ESCC), so as to assess whether it could be a novel biomarker for prognosis and prediction of response to therapy on ESCC patients. Methods The method of quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure LOC285194 expression in pretreatment biopsy specimens and matched normal tissue derived from ESCC patients who underwent preoperative chemoradiotherapy followed by surgical resection (CRT + S group; n = 55) or from those who received surgical resection alone (S group; n = 87). The association between LOC285194 expression and clinicopathological features and prognosis were then analyzed. Results LOC285194 expression was significantly down-regulated in ESCC tumor tissues when compared with the adjacent normal tissues ( p < 0.001). Low expression of LOC285194 was associated with larger tumor size (p = 0.002), advanced TNM stage ( p = 0.018), more lymph node metastases ( p = 0.013) and distant metastases ( p = 0.015). In the CRT + S group, the pathological complete response rate was 57% (16/28) for the LOC285194-high group, and 15% (4/27) for the LOC285194-low group. Univariate analysis revealed that low expression of LOC285194 was significantly correlated with CRT response ( p = 0.002). Moreover, Kaplan-Meier survival analysis revealed that patients with low expression of LOC285194 had a decreased disease free survival (DFS) ( p < 0.001) and overall survival (OS) ( p < 0.001). Multivariable analysis further identified low expression of LOC285194 as an independent prognosis factor for CRT response ( p = 0.011), DFS ( p < 0.001) and OS ( p = 0.002). Conclusion Decreased expression of LOC285194 could serve as a molecular marker to predict the clinical outcome of ESCC patients after surgery, and select patients who would benefit from preoperative CRT.

The Relationship Between the Thymidylate Synthase Mrna Expression and Clinical Prognostic in Esophageal Squamous Cell Carcinoma Patients Treated with 5-Flurouracil-based Chemotherapy

Correlation Between Expressions of Estrogen Receptor, Thymidylate Synthase and CAF Regime Sensibility in Breast Carcinoma

Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability

Detection of Cell-Free ERCC1 and Thymidylate Synthase (TS) Mrna in Malignant Effusions and Its Association with Anticancer Drug Sensitivity.

Predictive Value of Thymidylate Synthase Expression in Advanced Colorectal Cancer Patients Receiving Fluoropyrimidine‐based Chemotherapy: Evidence from 24 Studies

Correlations Between Serum Levels of TS, TP and Clinical Outcome in Chinese Patients with Advanced & Nbsp;gastric Cancer Receiving Fluorouracil-Based Chemotherapy

Correlated Analysis of 5 Fluorouracil Metabolic Enzymes with Tumor Response after SOX Regimen Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Thymidylate synthase expression in colon carcinomas with microsatellite instability

Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term

Title Stemness and Chemotherapeutic Drug Resistance Induced ByEif 5 a 2 Overexpression in Esophageal Squamous Cell Carcinoma

Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer

Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites

Thymidylate synthase promotes esophageal squamous cell carcinoma growth by relieving oxidative stress through activating nuclear factor erythroid 2-related factor 2 expression

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma

Expressions of the Genes Related to Chemotherapeutic Sensitivity in Non-Small Cell Lung Cancer and Their Correlation to Its Clinical Pathology

Expression profile and function of secretogranin V, and its effects on the malignant behavior of esophageal squamous cell carcinoma

Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis

The Expression of TS,ERCC1 in Colorectal Carcinoma and Their Clinical Significance